Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons prof. dr. H.J. (Hiddo) Lambers Heerspink

Publicaties

Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD

Proteins and signalling pathways targeted by dapagliflozin and finerenone: Insights from DAPA-CKD and FIGARO-DKD

Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial

Albuminuria Responses to Dapagliflozin in Patients With Type 2 Diabetes: A Crossover Trial

A Strategic Roadmap to Support Communication on and Acceptance of Surrogate Endpoints: The REnal Surrogacy accEpTance in Chronic Kidney Disease (RESET CKD) Collaboration

Authors' Reply: Effects of Zibotentan and Dapagliflozin on Fluid Retention in Patients with CKD: Need More Evidence

Authors’ Reply: Unlocking the Potential of SC0062: A New Horizon in IgA Nephropathy Treatment?

Canagliflozin and iron metabolism in the CREDENCE trial

Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial

Pers/media

Finerenone Improves UACR in T1D, CKD

'Nieuw' medicijn vermindert nierschade bij diabetespatiënten

Bayer Aktie: Neue Finanzchefin und Studienerfolg

Kidney drug trial raises hopes for new type 1 diabetes treatment

Hoe afslankmedicijnen het hele lichaam veranderen: ‘Mijn hoofd roept niet meer om eten’

智康弘义宣布SC0062临床II期糖尿病肾病队列研究达到12周主要终点 | 项目进展

Diabetesmedicijn Ozempic heeft ook positief effect bij chronische nierschade

Semaglutide in patinenten met nierziekte